IP Library Granted Patent US 10,086,084
Granted Patent B2
US 10,086,084 · App. 15/453,686 · Granted Oct 2, 2018

Activated polyoxazolines and conjugates and compositions comprising the same

Inventors: J Milton Harris (Huntsville, AL); Michael David Bentley (Huntsville, AL); Kunsang Yoon (Madison, AL); Zhihao Fang (Madison, AL); Francesco Maria Veronese (Padova, IT); Tacey Viegas (Madison, AL)
Assignee: Serina Therapeutics, Inc.
A61K47/48207A61K31/727A61K31/728A61K38/1816A61K38/193A61K38/27A61K38/33A61K38/42A61K38/47C08G69/48C12Y302/01017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,086,084
App. No.
15/453,686
Granted
Oct 2, 2018
Kind
B2
Abstract

The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

Claims (20)

1. A terminally activated polyoxazoline (POZ) compound of the general structure

R 1 —[N(COR 7 )CH 2 CH 2 ] n —P p -Q q -X,

wherein:

X is an active functional group capable of forming a linkage with a target molecule wherein all the linkages between the target molecule and the POZ compound are stable in a biological system;

P is NH;

Q is a linking group;

R 7 is independently selected for each repeating unit of POZ from an unsubstituted or substituted alkyl, alkenyl or aralkyl group;

R 1 is hydrogen, unsubstituted or substituted alkyl, alkenyl or aralkyl group;

n is an integer from 3 to 1000;

p is one; and

q is an integer independently selected from zero or one,

wherein all the linkages in the POZ compound are stable in a biological system.

2. The compound of claim 1 , wherein R 7 is methyl, ethyl or n-propyl.

3. The compound of claim 1 , wherein the active functional group is selected from the group consisting of: aldehydes, active carbonates, maleimides, sulfonate esters, tresylate, mesylate, hydrazide, epoxides, iodoacetamides, alkynes, azides, isocyanates, cyanates isothiocyanates, thiocyanates, nitriles, carbonyldiimidazole derivatives, vinylsulfones, carboxylic acid halides, active esters and carboxylic acids.

4. The compound of claim 1 , wherein NR 11 forms a substituted or unsubstituted piperazinyl or a substituted or unsubstituted piperidinyl group.

5. The compound of claim 1 , wherein the POZ polymer has a polydispersity value of less than or equal to 1.05.

6. The compound of claim 1 , wherein the compound is terminally activated.

7. The compound of claim 1 linked to the target molecule.

8. The compound of claim 1 , wherein the POZ polymer has a polydispersity value less than or equal to 1.2.

9. The compound of claim 1 , wherein the POZ polymer has a polydispersity value less than or equal to 1.1.

Assignments (3)
CHANGE OF NAME Recorded Apr 8, 2024
From: SERINA THERAPEUTICS, INC.
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 067036/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2018
From: VIEGAS, TACEY
To: SERINA THERAPEUTICS, INC.
Reel/Frame 046992/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2018
From: BENTLEY, MICHAEL DAVID; HARRIS, J. MILTON; YOON, KUNSANG; FANG, ZHIHAO; VERONESE, FRANCESCO MARIA
To: SERINA THERAPEUTICS, INC.
Reel/Frame 046639/0444 →
Continuity (9)
Continuation 14663863 · Mar 20, 2015
Continuation 13961576 · Aug 7, 2013
Continuation 13676048 · Nov 13, 2012
Continuation 13276910 · Oct 19, 2011
Continuation 12622264 · Nov 19, 2009
Continuation In Part 15529001
Provisional Application 61116246 · Nov 19, 2008
Provisional Application 60892212 · Feb 28, 2007
Related Publication 20170173171A1 · Jun 22, 2017